Abstract:Background: Mucorales infections continue to cause significant morbidity and mortality in immunocompromised hosts despite the advent of new approaches for diagnosis and treatment of fungal infections. We aimed to evaluate risk factors and outcomes of Mucorales infection in solid organ transplant, hematopoietic cell transplant, and chimeric antigen receptor T-cell therapy recipients. Methods: This single-center retrospective study included solid organ transplant, hematopoietic cell transplant, and chimeric antigen receptor T-cell patients with cultures positive for Mucorales. Results: Forty-three patients were included for analysis; 34 solid organ transplant (79%) and 9 hematopoietic stem cell transplant or chimeric antigen receptor T-cell (21%). Infection with Mucorales occurred a median of 184 days after transplant. At the time of diagnosis, 36 patients were on antifungal prophylaxis with the majority receiving posaconazole (53%). Thirty-three had clinically significant disease; 30 received definitive anti-Mucorales therapy and 3 empiric antifungal therapy. Isavuconazole was the most common azole used for treatment in monotherapy recipients. All-cause mortality was 64% and, of these deaths, 18 (75%) were directly related to Mucormycosis. The highest mortality was seen in disseminated and intra-abdominal disease (100%), followed by pulmonary disease (50%). There was no significant association with mortality and transplant type or number of immunosuppressive agents. Conclusion: Mucormycosis is an important cause of morbidity and mortality in immunocompromised patients. Breakthrough infection was not uncommon in this study. Data regarding the incidence of infection at approximately 6 months after transplantation can inform prophylaxis and treatment regimens. The spectrum of antifungal regimens used reflects the lack of consensus on ideal regimens for these organisms and a need for more studies.

Pathogenesis of mucormycosis

Fatal Gastrointestinal Mucormycosis in an Immunocompetent Patient : a Case Report and Review of the Literature

Epidemiology and treatment of mucormycosis

Mucormycosis in Renal Transplant Recipients: Review of 174 Reported Cases.

From Spores to Solutions: A Comprehensive Narrative Review on Mucormycosis

Epidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review

Epidemiology, Modern Diagnostics, and the Management of Mucorales Infections

Epidemiology and clinical manifestations of mucormycosis

Pulmonary mucormycosis

Future directions in mucormycosis research

Mucormycosis treatment: Recommendations, latest advances, and perspectives

Molecular mechanisms that govern infection and antifungal resistance in Mucorales

Prospective antifungal therapy (PATH) alliance®: focus on mucormycosis

Mucormycosis: A Case Series

Fatal Mucormycosis in a Diabetic Patient: A Case Report and Review of Diagnostic Challenges

Recent Advances in Diagnostic Approaches for Mucormycosis

Mucormycosis in organ and stem cell transplant recipients

[Clinical High Risk Factors and Prognosis of 25 Pulmonary Mucormycosis Cases].

Epidemiology, clinical manifestations, and outcome of mucormycosis in solid organ transplant recipients: a systematic review of reported cases

Risk Factors and Outcomes of Mucorales Infection in a Modern Cohort of Solid Organ Transplant, Hematopoietic Cell Transplant, and Chimeric Antigen Receptor T-cell Therapy Recipients

How I treat mucormycosis